Latest From BioNTech AG
Century Therapeutics brings in $250m for its cell therapy programs in a series A round, while immunotherapy specialist BioNTech sets a record for series B, raising $350m. Another five firms brought in rounds of $100m or greater...
Private Company Edition: IPOs and M&A are returning money to investors, who are putting that money into new investments. Also, the mega-push in VC mega-rounds continues, including $105m for Kronos, and RA Capital raises it first VC fund.
Private Company Edition: Revolution Medicines follows its Sanofi partnership and Warp Drive Bio buyout with a series C venture capital round to fund its RAS pathway inhibitors in cancer. The financing came during a boom in $100m-plus VC financings, including BioNTech's $325m series B.
Mainz-based BioNTech raises $325m in an upsized series B round to further advance its individualized immuno-oncology pipeline and manufacturing infrastructure.
- Antisense, Oligonucleotides
- Gene Therapy, Cell Therapy
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Areas
- Infectious & Viral Diseases
- Western Europe
- Parent & Subsidiaries
- BioNTech AG
- Senior Management
Ugur Sahin, MD, CEO
Sierk Poetting, PhD, CFO & COO
Sean Marett, CBO & Chief Commercial Officer
Özlem Türeci , MD, CMO
- Contact Info
Phone: 6131 9084 0
An der Goldgrube 12
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.